share_log

12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga ·  Mar 10, 2023 05:31

Gainers

  • Lucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 9.4% to $1.86 during Thursday's after-market session. The market value of their outstanding shares is at $30.2 million.
  • Lipocine (NASDAQ:LPCN) shares increased by 8.4% to $0.46. The company's market cap stands at $40.2 million.
  • Matinas BioPharma Hldgs (AMEX:MTNB) stock moved upwards by 7.34% to $0.51. The market value of their outstanding shares is at $110.6 million.
  • Bio-Path Holdings (NASDAQ:BPTH) shares rose 7.05% to $1.67. The company's market cap stands at $13.2 million.
  • Aridis Pharmaceuticals (NASDAQ:ARDS) shares increased by 7.0% to $0.5. The company's market cap stands at $12.8 million.
  • NeuBase Therapeutics (NASDAQ:NBSE) shares rose 6.96% to $0.21. The company's market cap stands at $7.1 million.

Losers

  • AlloVir (NASDAQ:ALVR) shares decreased by 6.4% to $4.56 during Thursday's after-market session. The market value of their outstanding shares is at $426.1 million.
  • Bullfrog AI Hldgs (NASDAQ:BFRG) stock declined by 6.3% to $3.57. The market value of their outstanding shares is at $20.1 million.
  • Intelligent Bio Solutions (NASDAQ:INBS) stock decreased by 5.85% to $2.9. The market value of their outstanding shares is at $2.6 million.
  • RenovoRx (NASDAQ:RNXT) shares decreased by 5.09% to $4.29. The company's market cap stands at $39.0 million.
  • Entrada Therapeutics (NASDAQ:TRDA) shares fell 5.0% to $11.4. The company's market cap stands at $377.0 million. As per the press release, Q4 earnings came out 3 days ago.
  • Alaunos Therapeutics (NASDAQ:TCRT) stock decreased by 4.9% to $0.56. The market value of their outstanding shares is at $134.8 million. As per the press release, Q4 earnings came out 2 days ago. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment